首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1535657

免疫螢光檢測市場規模 - 按產品（抗體、試劑盒和試劑、儀器、消耗品和配件）、類型（間接和直接免疫螢光）、應用（癌症、傳染病）、最終用途和預測，2024 - 2032

Immunofluorescence Assay Market Size - By Product (Antibodies, Kits & Reagents, Instruments, Consumables & Accessories), Type (Indirect & Direct Immunofluorescence), Application (Cancer, Infectious Diseases), End-use & Forecast, 2024 - 2032

出版日期: 2024年06月12日 | 出版商:

Global Market Insights Inc. | 英文 167 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於慢性病盛行率不斷上升以及對準確和早期診斷工具的需求不斷成長，預計免疫螢光檢測市場規模在 2024 年至 2032 年期間複合年成長率將達到 5.1%。免疫螢光測定 (IFA) 對於檢測和量化與癌症、自體免疫疾病和傳染病等疾病相關的特定生物標記至關重要。隨著這些疾病的全球發病率持續上升，越來越需要可靠的診斷技術來提供準確和及時的資訊。據世界衛生組織稱，到 2050 年，心血管疾病、癌症、糖尿病和呼吸系統疾病等慢性疾病預計每年將導致 9,000 萬人死亡。

螢光染料、抗體和檢測系統的創新也將增強 IFA 的性能和多功能性，以實現更詳細和準確的分析。製藥和生技公司對研發活動的投資不斷增加，以促進創建具有增強功能的新型免疫螢光解決方案，這將推動市場成長。

整個產業分為產品、類型、應用、最終用途和地區。

從產品來看，由於先進的成像和檢測系統在提高這些檢測的準確性和效率方面發揮關鍵作用，儀器領域的 IFA 市場預計將在 2024 年至 2032 年期間顯著成長。螢光顯微鏡、自動成像系統和專用偵測器等精密儀器對於高精度可視化和量化螢光訊號至關重要。

由於對快速、精確的診斷方法來識別和管理傳染性病原體的需求不斷增加，預計到 2032 年，傳染病應用領域的免疫螢光檢測產業規模將大幅成長。免疫螢光測定在檢測與多種傳染病（包括病毒、細菌和寄生蟲感染）相關的特定抗原方面非常有效。

由於醫療保健基礎設施的不斷擴大和研發活動的大量投資，預計亞太地區免疫螢光檢測市場將在 2024 年至 2032 年期間大幅成長。生物技術的快速進步和對增強診斷能力的高度重視正在推動對複雜免疫螢光測定的需求。傳染病和慢性病負擔的日益增加，加上醫療保健支出的增加以及政府改善疾病管理的措施將進一步刺激該區域市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 慢性病盛行率增加
  - 免疫螢光檢測技術的進步
  - 不斷成長的研發活動
  - 現場檢測的採用率不斷上升
- 產業陷阱與挑戰
  - 儀器成本高
成長潛力分析
報銷場景
監管環境
技術景觀
- 核心技術
- 鄰近技術
2023 年定價分析
- 按地區
- 按關鍵人物
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
抗體
試劑盒和試劑
儀器儀表
耗材及配件

第 6 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
間接免疫螢光
直接免疫螢光

第 7 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
癌症
傳染病
心血管疾病
自體免疫疾病
其他疾病

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
學術及研究機構
製藥和生物技術公司
合約研究組織
醫院和診斷中心

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Cell Signaling Technology, Inc.
Danaher Corporation
EpigenTek Group Inc.
MaxVision Biosciences Inc.
Medipan GmbH
Merck & Co., Inc.
J. Mitra & Co. Pvt. Ltd.
Nikon Corporation
Olympus Corporation
PerkinElmer, Inc.
Sino Biological, Inc.
Thermo Fisher Scientific Inc.
Werfen

簡介目錄

Product Code: 9818

Immunofluorescence assay market size is anticipated to witness 5.1% CAGR between 2024 and 2032 driven by the increasing prevalence of chronic diseases along with the rising demand for accurate and early diagnostic tools. Immunofluorescence assays (IFA) are crucial for detecting and quantifying specific biomarkers associated with diseases, such as cancer, autoimmune disorders, and infectious diseases. As the global incidence of these conditions is continuing to rise, there is growing need for reliable diagnostic techniques to provide precise and timely information. As per WHO, by 2050, chronic diseases, such as cardiovascular conditions, cancer, diabetes, and respiratory illnesses are projected to account 90 million deaths annually.

Innovations in fluorescent dyes, antibodies, and detection systems will also enhance the performance and versatility of IFAs for more detailed and accurate analyses. The increasing investments in R&D activities by pharmaceutical and biotechnology companies for fostering the creation of novel immunofluorescence solutions with enhanced capabilities will drive the market growth.

The overall industry is classified into product, type, application, end-use and region.

Based on product, the IFA market from the instruments segment is slated to witness significant growth during 2024-2032 due to the critical role that advanced imaging and detection systems play in enhancing the accuracy and efficiency of these assays. Sophisticated instruments, such as fluorescence microscopes, automated imaging systems, and specialized detectors are essential for visualizing and quantifying fluorescent signals with high precision.

Immunofluorescence assay industry size from the infectious disease application segment is anticipated to witness substantial growth through 2032 owing to the increasing need for rapid and precise diagnostic methods to identify and manage infectious pathogens. Immunofluorescence assays are highly effective in detecting specific antigens associated with a wide range of infectious diseases, including viral, bacterial, and parasitic infections.

Asia Pacific immunofluorescence assay market is anticipated to grow at a significant pace over 2024-2032 attributed to the expanding healthcare infrastructure and hefty investments in R&D activities. Rapid advancements in biotechnology and the strong emphasis on enhancing diagnostic capabilities are fueling the demand for sophisticated immunofluorescence assays. The growing burden of infectious and chronic diseases, coupled with the rising healthcare expenditure and government initiatives to improve disease management will further stimulate the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic diseases
  - 3.2.1.2 Technological advancements in immunofluorescence assays
  - 3.2.1.3 Growing research and development activities
  - 3.2.1.4 Rising adoption of point-of-care testing
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of instruments
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technological landscape
- 3.6.1 Core technologies
- 3.6.2 Adjacent technologies
3.7 Pricing analysis, 2023
- 3.7.1 By region
- 3.7.2 By key player
3.8 Future market trends
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Antibodies
5.3 Kits and reagents
5.4 Instruments
5.5 Consumables and accessories

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Indirect immunofluorescence
6.3 Direct immunofluorescence

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cancer
7.3 Infectious diseases
7.4 Cardiovascular diseases
7.5 Autoimmune diseases
7.6 Other diseases

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Academic & research institutes
8.3 Pharmaceutical & biotechnology companies
8.4 Contract research organizations
8.5 Hospitals & diagnostic centers

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa